Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03214588 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT03214588 is a Phase 2 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 67 participants.
The verdict
NCT03214588, a Phase 2 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of TAK-831 versus placebo on upper extremity (arm and hands) motor function and manual dexterity. This study will also evaluate the efficacy of TAK-831 versus placebo on activities of daily living (ADL) and other secondary assessments.
Interventions
- DRUG TAK-831
- DRUG TAK-831 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2017-11-08 |
| Est. Completion | 2018-12-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03214588
The ClinicalTrials.gov registry entry for NCT03214588 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-831 is the first listed.
NCT03214588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03214588 about?
NCT03214588 is a clinical study titled "Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia". The purpose of this study is to evaluate the efficacy of TAK-831 versus placebo on upper extremity (arm and hands) motor function and manual dexterity. This study will also evaluate the efficacy of TAK-831 versus placebo on activities of daily living (ADL) and other secondary assessments.
What is the current status of trial NCT03214588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2017-11-08. Estimated completion is 2018-12-27.
What interventions are being tested in trial NCT03214588?
The interventions under investigation include: TAK-831 (DRUG), TAK-831 Placebo (DRUG).
Who is sponsoring clinical trial NCT03214588?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.